GERN Key Statistics, Chart & Performance
The current stock price of GERN is 1.345 USD. In the past month the price increased by 21.3%. In the past year, price decreased by -66.67%.
GERN Latest News, Press Relases and Analysis
GERN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.82 | 397.78B | ||
| AMGN | AMGEN INC | 14.9 | 175.44B | ||
| GILD | GILEAD SCIENCES INC | 14.84 | 150.76B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.06 | 114.76B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.76 | 74.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 871.28 | 58.70B | ||
| INSM | INSMED INC | N/A | 43.58B | ||
| NTRA | NATERA INC | N/A | 33.81B | ||
| BIIB | BIOGEN INC | 10.79 | 26.51B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.41 | 20.92B | ||
| INCY | INCYTE CORP | 15.16 | 19.11B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.19B |
Related stock screener links
About GERN
Company Profile
Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 229 full-time employees. The firm develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. The company is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Company Info
GERON CORP
919 East Hillsdale Boulevard, Suite 250
Foster City CALIFORNIA 94404 US
CEO: John A. Scarlett
Employees: 229
Phone: 16504737700
GERON CORP / GERN FAQ
Can you describe the business of GERON CORP?
Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 229 full-time employees. The firm develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. The company is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
What is the current price of GERN stock?
The current stock price of GERN is 1.345 USD. The price increased by 2.67% in the last trading session.
What is the dividend status of GERON CORP?
GERN does not pay a dividend.
How is the ChartMill rating for GERON CORP?
GERN has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists GERN stock?
GERN stock is listed on the Nasdaq exchange.
What is GERON CORP worth?
GERON CORP (GERN) has a market capitalization of 858.59M USD. This makes GERN a Small Cap stock.
GERN Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to GERN. When comparing the yearly performance of all stocks, GERN is a bad performer in the overall market: 91.97% of all stocks are doing better.
GERN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GERN. The financial health of GERN is average, but there are quite some concerns on its profitability.
GERN Financial Highlights
Over the last trailing twelve months GERN reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS increased by 62.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.04% | ||
| ROE | -32.02% | ||
| Debt/Equity | 0.48 |
GERN Forecast & Estimates
13 analysts have analysed GERN and the average price target is 3.4 USD. This implies a price increase of 152.79% is expected in the next year compared to the current price of 1.345.
For the next year, analysts expect an EPS growth of 57.19% and a revenue growth 150.96% for GERN